Skip to main content
×
×
Home

Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials

  • Egemen Savaskan (a1), Heiko Mueller (a2), Robert Hoerr (a2), Armin von Gunten (a3) and Serge Gauthier (a4)...
Abstract
Background:

In randomized controlled trials, Ginkgo biloba extract EGb 761® has been found to be effective in the treatment of behavioral and psychological symptoms of dementia (BPSD).

Methods:

To assess the effects of EGb 761® on specific BPSD, we analyzed data from all randomized, placebo-controlled, at least 20-week, trials of EGb 761® enrolling patients with dementia (probable Alzheimer's disease (AD), probable vascular dementia or probable AD with cerebrovascular disease) who had clinically significant BPSD (Neuropsychiatric Inventory (NPI) total score at least 6). Data were pooled and joint analyses of NPI single item composite and caregiver distress scores were performed by meta-analysis with a fixed effects model.

Results:

Four trials involving 1628 patients (EGb 761®, 814; placebo, 814) were identified; treatment duration was 22 or 24 weeks; the daily dose of EGb 761® was 240 mg in all trials. Pooled analyses including data from the full analysis sets of all trials (EGb 761®, 796 patients; placebo, 802 patients) revealed significant superiority of EGb 761® over placebo in total scores and 10 single symptom scores. Regarding caregiver distress scores, EGb 761®-treated patients improved significantly more than those receiving placebo in all symptoms except delusions, hallucinations, and elation/euphoria. The benefit of EGb 761® mainly consists of improvement in symptoms present at baseline, but the incidence of some symptoms was also decreased.

Conclusions:

Twenty two- to twenty four-week treatment with Ginkgo biloba extract EGb 761® improved BPSD (except psychotic-like features) and caregiver distress caused by such symptoms.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence should be addressed to: Robert Hoerr, MD, PhD, Dr. Willmar Schwabe GmbH & Co. KG Willmar-Schwabe-Str. 4, 76227 Karlsruhe, Germany. Phone: +49 721 4005-492; Fax: +49 721 4005-8492. E-mail: robert.hoerr@schwabe.de.
References
Hide All
Bachinskaya, N., Hoerr, R. and Ihl, R., for the GOTADAY Study Group. (2011). Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial. Neuropsychiatric Disease and Treatment, 7, 209215.
Cummings, J. L. (1997). The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology, 48, S10S16.
Cummings, J. L. and McPherson, S. (2001). Neuropsychiatric assessment of Alzheimer's disease and related dementias. Aging Clinical and Experimental Research, 13, 240246.
Gauthier, S. et al. (2010). Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22, 346372.
Gauthier, S., Wirth, Y. and Möbius, H. J. (2005). Effects of memantine on behavioral symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. International Journal of Geriatric Psychiatry, 20, 459464.
Geda, Y. E. et al. (2013). Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimer's and Dementia, 9, 602608.
Halama, P., Bartsch, G. and Meng, G. (1988). Hirnleistungsstörungen vaskulärer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo-biloba-Extrakt [Cerebrovascular insufficiency – Placebo-controlled, randomised, doubleblind trial on the effect of Ginkgo biloba extract]. Fortschritte der Medizin, 106, 408412.
Herrschaft, H., Nacu, A., Likhachev, S., Sholomov, I., Hoerr, R. and Schlaefke, S. (2012). Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. Journal of Psychiatric Research, 46, 716723.
Hoerr, R. (2003). Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761®. Pharmacopsychiatry, 36, S56–S61.
Hyde, A. J. et al. (2016). Herbal medicine for management of the behavioral and psychological symptoms of dementia (BPSD): a systematic review and meta-analysis. Journal of Psychopharmacology, online ahead of print. doi: 10.1177/0269881116675515.
Ihl, R. et al. (2011). Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. International Journal of Geriatric Psychiatry, 26, 11861194. doi: 10.1002/gps.2662.
Jönsson, L. et al. (2006). Determinants of costs of care for patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 21, 449459.
Karttunen, K. et al. (2011). Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. International Journal of Geriatric Psychiatry, 26, 473482.
Kim, Y. S., Nibbelink, D. W. and Overall, J. E. (1993). Factor structure and scoring of the SKT test battery. Journal of Clinical Psychology, 49, 6171.
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C. and Breitner, J. C. S. (2000). Mental and behavioral disturbances in dementia: findings from the cache county study on memory in aging. American Journal of Psychiatry, 157, 708714.
Mahoney, R., Johnston, K., Katona, C., Maxmin, K. and Livingston, G. (2005). The TE4D-Cog: a new test for detecting early dementia in english-speaking populations. International Journal of Geriatric Psychiatry, 20, 11721179.
McKhann, G. M. et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7, 263269.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology, 34, 939944.
McShane, R., Areosa Sastre, A. and Minakaran, N. (2006). Memantine for dementia. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003154. doi: 10.1002/14651858.CD003154.pub5.
Nacu, A. and Hoerr, R. (2016). Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial. Open Access Journal of Clinical Trials, 8, 16.
Napryeyenko, O., Borzenko, I. and the GINDEM-NP Study Group. (2007). Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung, 57, 411.
Nikolova, G., Yancheva, S., Raychev, I. and Hoerr, R., for the PLAGIN Study Group. (2013). Ginkgo biloba extract in dementia: a 22-week randomised, placebo-controlled, double-blind trial. Bulgarian Neurology, 14, 139143.
Porsteinsson, A. P. et al. (2014). Effect of citalopram on agitation in Alzheimer disease. The CitAD randomized clinical trial. Journal of the American Medical Association, 311, 682691.
Rodda, J., Morgan, S. and Walker, Z. (2009). Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. International Psychogeriatrics, 21, 813824.
Román, G. C. et al. (1993). Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250260.
Scripnikov, A., Khomenko, A. and Napryeyenko, O., for the GINDEM-NP Study Group. (2007). Effects of Ginkgo biloba extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wiener Medizinische Wochenschrift, 157, 295300.
Tan, L. et al. (2015). Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer's Research and Therapy, 7, 20.
Tchantchou, F. et al. (2009). Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. Journal of Alzheimer's Disease, 18, 787798.
Tun, S. M., Murman, D. L., Long, H. L., Colenda, C. C. and von Eye, A. (2007). Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 15, 314327.
von Gunten, A., Schlaefke, S. and Überla, K. (2016). Efficacy of Ginkgo biloba Extract EGb 761® in dementia with behavioral and psychological symptoms: a systematic review. The World Journal of Biological Psychiatry, 18, 622633.
Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C. and Willich, S. N. (2010). Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics, 10, 14.
Yancheva, S., Ihl, R., Nikolova, G., Panayotov, P., Schlaefke, S. and Hoerr, R. for the GINDON Study Group. (2009). Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging and Mental Health, 13, 183190.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score